The most active of these derivatives was the l-Trp derivative (88, PCM126) (Table 5), which, at low micromolar concentrations, significantly outperformed LCA in terms of breaking the EphA2–ephrinA1 connection and decreasing EphA2 phosphorylation in prostate cancer cells. The gene discussed is EPHA2; the disease is prostate cancer.